Terms: = Ovarian cancer AND TFE3, RCCP2, 7030, ENSG00000068323, TFEA AND Diagnosis
4 results:
1. tfe3 nuclear expression as a novel biomarker of ovarian sclerosing stromal tumors and associated with its histological morphology.
Zhao L; Yang Z; Zhou Y; Liu Y; Luo Q; Jiang Q; Wang H; Wang N
J Ovarian Res; 2023 Aug; 16(1):152. PubMed ID: 37528481
[TBL] [Abstract] [Full Text] [Related]
2. Case Report: Ectopic Adrenocortical Carcinoma in the Ovary.
Tsai WH; Chen TC; Dai SH; Zeng YH
Front Endocrinol (Lausanne); 2021; 12():662377. PubMed ID: 33815299
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological Characteristics of ovarian Sclerosing Stromal Tumor with an Emphasis on tfe3 Overexpression.
Park CK; Kim HS
Anticancer Res; 2017 Oct; 37(10):5441-5447. PubMed ID: 28982854
[TBL] [Abstract] [Full Text] [Related]
4. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.
Palomar A; Nanni C; Castellucci P; Ambrosini V; Montini GC; Allegri V; Pettinato C; Al-Nahhas A; Soriano A; Grassetto G; Rubello D; Fanti S
Mol Imaging Biol; 2012 Feb; 14(1):123-9. PubMed ID: 21240639
[TBL] [Abstract] [Full Text] [Related]
